Nishiyama T, Matsumoto Y, Watanabe H, Fujiwara M, Sato S
J Natl Cancer Inst. 1987 Jun;78(6):1113-8.
Recently, several investigators have demonstrated that the MN blood group precursor antigens Thomsen-Friedenreich antigen (T-Ag) and Tn-antigen (Tn-Ag) are expressed on the cell surfaces of several cancers, including urinary bladder cancer. T-Ag is composed of a specific carbohydrate chain, galactose-beta-1-3-N-acetylgalactosamine (GalNAc), which is specifically detectable through the immunohistochemical binding of peanut agglutinin (PNA). In normal cells, T-Ag is cryptic (cT-Ag) and can be unmasked by treatment with neuraminidase. Tn-Ag is composed of another carbohydrate chain, alpha-GalNAc-serine/threonine, and binds specifically to Vicia villosa agglutinin (VVA). With the use of both these lectins, VVA and PNA, the presence or absence of Tn-Ag and T-Ag was examined in 24 specimens of normal bladder epithelium and specimens from 53 cases of human urinary bladder transitional cell carcinoma of various histologic grades by staining paraffin sections by means of the avidin-biotin-immunoperoxidase technique. The correlation between the expression of these antigens and the patient's clinical course was then estimated. Out of 21 patients in whom the tumors expressed the phenotype Tn-Ag(+), T-Ag(+), or cT-Ag(-), 17 suffered from invasive recurrence. Although patients with tumors expressing the phenotypes T-Ag(-) and cT-Ag(+) have been reported to show a good clinical course, in our studies some of them showed a switch to invasive recurrence. Thus it was not possible to estimate the patient's clinical course only by the presence or absence of T-Ag and cT-Ag. The expression of Tn-Ag was then examined with the use of VVA. Of 38 cases expressing the phenotypes T-Ag(-) and cT-Ag(+), 6 had tumors that carried Tn-Ag; 5 of them suffered from invasive recurrence. These results indicated that the detection of Tn-Ag with the use of VVA in combination with the examination of T-Ag and cT-Ag is useful for estimating the degree of malignancy of bladder cancer and the patient's clinical course.
最近，几位研究者证实，MN血型前体抗原——汤姆森－弗里德赖希抗原（T抗原）和Tn抗原（Tn-Ag）在包括膀胱癌在内的多种癌症的细胞表面表达。T抗原由一条特定的碳水化合物链——半乳糖-β-1-3-N-乙酰半乳糖胺（GalNAc）组成，可通过花生凝集素（PNA）的免疫组化结合进行特异性检测。在正常细胞中，T抗原是隐蔽的（cT-Ag），可通过神经氨酸酶处理使其暴露。Tn抗原由另一条碳水化合物链——α-GalNAc-丝氨酸/苏氨酸组成，并与绒毛野豌豆凝集素（VVA）特异性结合。利用这两种凝集素，即VVA和PNA，通过抗生物素蛋白-生物素-免疫过氧化物酶技术对石蜡切片进行染色，检测了24例正常膀胱上皮标本和53例不同组织学分级的人膀胱移行细胞癌标本中Tn-Ag和T-Ag的有无。然后评估了这些抗原的表达与患者临床病程之间的相关性。在21例肿瘤表达Tn-Ag(+)、T-Ag(+)或cT-Ag(-)表型的患者中，有17例发生侵袭性复发。尽管有报道称，肿瘤表达T-Ag(-)和cT-Ag(+)表型的患者临床病程良好，但在我们的研究中，其中一些患者出现了向侵袭性复发的转变。因此，仅根据T-Ag和cT-Ag的有无无法评估患者的临床病程。随后利用VVA检测了Tn-Ag的表达。在38例表达T-Ag(-)和cT-Ag(+)表型的病例中，有6例肿瘤携带Tn-Ag；其中5例发生侵袭性复发。这些结果表明，利用VVA检测Tn-Ag并结合检测T-Ag和cT-Ag，有助于评估膀胱癌的恶性程度和患者的临床病程。
